Covaxin, one of the main vaccines used in the Indian Coronavirus immunization drive, only provides 50% protection against Covid-19 symptomatic, according to a real-world study that shows that shots are less effective than expected.
When India was slammed by the second main Covid wave of the year, the researchers at the All India Institute of Medical Sciences in Delhi analyzed data from 2,714 from hospital health workers who show signs of infection and undergo RT-PCR testing between April 15 and May 15 According to a study published in the Journal of Lancet Infection.
At the beginning of the state vaccination campaign in January, the staff at AIIMS were exclusively offered by Covaxin, a shot developed jointly by the Indian Medical Research Council (ICMR) and Bharat Biotech International Ltd.
based in Hyderabad found that two weeks or more after completing the two-weeks Dosage, customized effectiveness of vaccines against simtomatic covid is lower than 77.8% that the temporary results set during the final test, a study published in Lancet earlier this month.
The level of high infection and virus exposure among hospital employees may have contributed to the efficacy of the real world of Covaxin, along with the possibility that the Delta variant that had just emerged hit the protection of gunfire, the researchers said.
“Our study offers a more complete picture of how BBV152 appears in the field and must be considered in the context of Covid-19 surge conditions in India, combined with the possibility of potential to avoid the immune from the Delta variant,” additional professor) drugs in AIIMS in New Delhi, said in a statement referring to the scientific name of the vaccine.
While various studies show that almost all Covid vaccines showed a reduced effectiveness of a very contagious Delta variant, which began to rampant throughout India in early 2021, a new research on Covaxin could mention the inoculation appeal when Bharat Biotech was increasing manufacturing and Bharat.
When India began sending vaccines to abroad.
So far more than 130 million doses of covaxin have been given in India.
Bharat Biotech and the Indian government, which has been widely promoting shots, have tried to close the door to controversy involving the initial authorization of the vaccine in January before completing the phase 3 trial, encouraging widespread doubts in the country at that time.
The independent technical panel of the World Health Organization also took months before providing emergency approval to Covaxin in early November, repeatedly asked Bharat Biotech for further data.
Krishna Ella, the chairman of the Hyderabad-based vaccine maker, said The WHO Green Light took time because of criticism surrounding shots, which was developed using traditional viral technology that was inactive.
The researchers said the AIIMS study did not estimate the effectiveness of vaccines against hospitalization, severe illness and death, while recognizing that it was not designed to estimate protection at different time intervals.
Patients are not tested to find whether they are symptomatic because of certain variants and the author also points to a lack of data about comorbidity and previous infections.
Covaxin provides lower protection during the second wave: real world studies
